MILONTIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for MILONTIN (MILONTIN).
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
| Metabolism | Hepatic via glucuronidation and oxidation; CYP450 involvement minimal. |
| Excretion | Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces. |
| Half-life | Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels. |
| Protein binding | Negligible; less than 1% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.7–0.9 L/kg; clinical meaning: distribution consistent with total body water, indicating minimal tissue binding. |
| Bioavailability | Oral: nearly 100% (well absorbed from GI tract); no parenteral formulation available. |
| Onset of Action | Oral: 1–2 hours after a single dose; peak plasma concentrations at 2–4 hours; clinical effect on seizures typically within first few days. |
| Duration of Action | Duration of action is 4–6 hours after a single dose; clinical notes: short half-life necessitates dosing every 6 hours for seizure control. |
| Molecular Weight | 163.2 |
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
| Dosage form | CAPSULE |
| Renal impairment | CrCl < 50 mL/min: avoid use. No data for milder impairment. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Children 7-12 years: 300 mg orally twice daily initially; increase by 300 mg/day every 2-3 days; usual 600-1200 mg/day in 2-3 divided doses. Infants and children under 7: not recommended. |
| Geriatric use | Start at lower end of dosing range; monitor for sedation and falls; adjust based on renal function. |
| 1st trimester | Limited human data; animal studies show teratogenic effects (neural tube defects, congenital malformations) at high doses. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Use with caution; may cause fetal harm. Monitor fetal growth and development. |
| 3rd trimester | Use with caution; may cause neonatal withdrawal or sedation. Avoid near term if possible. |
Clinical note
Comprehensive clinical and safety monograph for MILONTIN (MILONTIN).
| Placental transfer | Crosses placenta; fetal serum levels approximate maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; case reports of infant drowsiness and poor feeding. Monitor infant for sedation and adequate weight gain. Consider alternative if high doses are used. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Phensuximide (Milontin) is an older succinimide anticonvulsant. Human data are limited, but animal studies have shown teratogenic effects. The risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies, is considered increased, especially with first-trimester exposure. Its use in pregnancy is generally avoided unless no safer alternative exists. The risk is highest during the first trimester (organogenesis). Second and third trimester exposure may be associated with growth restriction and neurodevelopmental effects, but data are sparse. |
| Fetal Monitoring | Monitor maternal serum drug levels (therapeutic range 40-100 mcg/mL) and adjust dose to maintain seizure control. Monitor for signs of toxicity (drowsiness, ataxia, dizziness, hematologic abnormalities). During pregnancy, perform fetal ultrasound for anomaly screening, consider fetal echocardiogram if first-trimester exposure. Assess fetal growth with serial ultrasounds in the second and third trimesters. Monitor for neonatal withdrawal or toxicity (hypotonia, respiratory depression) at delivery. |
| Fertility Effects | Limited data suggest that phensuximide may impair fertility in animal studies. In humans, the effect on fertility is unknown. Menstrual irregularities have been reported in women taking succinimides, but causality is not established. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to succinimidesSevere hepatic impairmentPorphyria
| Precautions | May cause drowsiness, dizziness; use caution with other CNS depressants; monitor for blood dyscrasias; withdraw gradually to avoid precipitating seizures. |
| Food/Dietary | No specific food interactions known. Maintain consistent alcohol intake; avoid excessive alcohol as it may lower seizure threshold. |
| Clinical Pearls | Milontin (phensuximide) is a succinimide anticonvulsant primarily used for absence seizures. It is a second-line agent after ethosuximide due to higher risk of adverse effects. Monitor for bone marrow suppression, including agranulocytosis and pancytopenia; obtain baseline and periodic CBCs. Hepatitis and nephrosis have been reported; assess liver and renal function periodically. Psychotic episodes may occur, especially in patients with prior psychiatric history. Taper gradually to avoid withdrawal seizures. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly as this can cause breakthrough seizures. · Report any signs of infection (fever, sore throat, mouth sores) immediately due to risk of blood disorders. · Notify your doctor if you experience unusual bleeding or bruising, dark urine, or jaundice. · Avoid driving or operating heavy machinery until you know how this medication affects you; it may cause drowsiness or dizziness. · Regular blood tests are required to monitor for side effects. · Use effective contraception if of childbearing age; discuss pregnancy plans with your doctor. |
Loading safety data…